Home › Research › Prevention and risk
Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease
Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J, PROGRESS Collaborative Group.. Archives of internal medicine, 2003-05-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Background High blood pressure and stroke are associated with increased risks of dementia and cognitive impairment. This study aimed to determine whether blood pressure lowering would reduce the risks of dementia and cognitive decline among individuals with cerebrovascular disease. Methods The Perindopril Protection Against Recurrent Stroke Study (PROGRESS) was a randomized, double-blind, placebo-controlled trial conducted among 6105 people with prior stroke or transient ischemic attack. Participants were assigned to either active treatment (perindopril for all participants and indapamide for those with neither an indication for nor a contraindication to a diuretic) or matching placebo(s). The primary outcomes for these analyses were dementia (using DSM-IV criteria) and cognitive decline (a decline of 3 or more points in the Mini-Mental State Examination score). Results During a mean follow-up of 3.9 years, dementia was documented in 193 (6.3%) of the 3051 randomized participants in the actively treated group and 217 (7.1%) of the 3054 randomized participants in the placebo group (relative risk reduction, 12% [95% confidence interval, -8% to 28%]; P =.2). Cognitive decline occurred in 9.1% of the actively treated group and 11.0% of the placebo group (risk reduction, 19% [95% confidence interval, 4% to 32%]; P =.01). The risks of the composite outcomes of dementia with recurrent stroke and of cognitive decline with recurrent stroke were reduced by 34% (95% confidence interval, 3% to 55%) (P =.03) and 45% (95% confidence interval, 21% to 61%) (P Conclusions Active treatment was associated with reduced risks of dementia and cognitive decline associated with recurrent stroke. These findings further support the recommendation that blood pressure lowering with perindopril and indapamide therapy be considered for all patients with cerebrovascular disease.
What this study adds
Evidence grade: High
This is a trial of 6,105 participants. In a double-blind trial of 6,105 people who had already had a stroke or TIA, followed for an average of 3.9 years, dementia occurred in 6.3% of those given perindopril (with indapamide for some) and 7.1% on placebo, a difference that was not statistically significant (P = .2). Reported effect size: 6.3%; 7.1%; 9.1%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tzourio, C., Anderson, C., Chapman, N., Woodward, M., Neal, B., MacMahon, S., et al. (2003). Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of internal medicine. https://doi.org/10.1001/archinte.163.9.1069
Vancouver
Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of internal medicine. 2003. doi:10.1001/archinte.163.9.1069. PMID: 12742805.
BibTeX
@article{tzourio2003-12742805,
author = {Tzourio, C. and Anderson, C. and Chapman, N. and Woodward, M. and Neal, B. and MacMahon, S. and Chalmers, J. and {PROGRESS Collaborative Group}},
title = {{Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease}},
journal = {Archives of internal medicine},
year = {2003},
doi = {10.1001/archinte.163.9.1069},
pmid = {12742805},
url = {https://doi.org/10.1001/archinte.163.9.1069}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Background High blood pressure and stroke are associated with increased risks of dementia and cognitive impairment.
- Results During a mean follow-up of 3.9 years, dementia was documented in 193 (6.3%) of the 3051 randomized participants in the actively treated group and 217 (7.1%) of the 3054 randomized participants in the placebo group (relative risk reduction, 12% [95% confidence interval, -8% to 28%]; P =.2).
- The risks of the composite outcomes of dementia with recurrent stroke and of cognitive decline with recurrent stroke were reduced by 34% (95% confidence interval, 3% to 55%) (P =.03) and 45% (95% confidence interval, 21% to 61%) (P<.001), respectively, with no clear effect on either dementia or cognitive decline in the absence of recurrent stroke.
- These findings further support the recommendation that blood pressure lowering with perindopril and indapamide therapy be considered for all patients with cerebrovascular disease.
Why it matters
In a double-blind trial of 6,105 people who had already had a stroke or TIA, followed for an average of 3.9 years, dementia occurred in 6.3% of those given perindopril (with indapamide for some) and 7.1% on placebo, a difference that was not statistically significant (P = .2). A drop of 3 or more points on the MMSE memory-screening test was less common with treatment (9.1% vs 11.0%, P = .01). The authors' positive conclusion is narrower: treatment was "associated with reduced risks of dementia and cognitive decline associated with recurrent stroke", for example a 34% lower risk of dementia together with a further stroke.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Participants6,105
- Effect size6.3%; 7.1%; 9.1%
- Evidence strengthHigh
How this study scored 77/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. We have no data on senior author's track record, so that was left out: it earned 74 of the 96 points we could judge it on, which is 77 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Archives of internal medicine) |
| Journal's citation record | 3 / 4 | Archives of Internal Medicine: journal h-index 462 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2003 — older than 20 years, still counted |
| Sample size | 3 / 4 | 6,105 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 6 / 7 | Cited 989 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 39.6 citations a year over 25 year(s) since 2003 |
| Impact for its field and year | 5 / 6 | Cited 28.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 54 other studies in this library |
| Still being cited | 3 / 4 | Cited 57 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 1 / 3 | The University of Sydney: institution h-index 1,466 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12742805) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 74 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 74 of the 96 points we could judge it on is 77 out of 100. |
| Total | 77 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/archinte.163.9.1069
- PubMed: 12742805
- Original source →
- Free full text: jamanetwork.com →
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
54 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Prevention and risk from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.